Table 8 Associations of IGF-1 and IGF-binding proteins with STC2, mutually adjusted for other members of the system members*.
n | β (95% CI) per 10 ng/mL§ | 95% CI | |
|---|---|---|---|
IGF-1, ng/ml | |||
As in Table 7 | 394 | − 2.4 | (− 4.7, − 0.2) |
- Plus adjustment for PAPP-A2 | 394 | − 2.1 | (− 4.3, 0.1) |
- Plus adjustment for PAPP-A (< LOD substituted, log-transformed) | 394 | − 2.3 | (− 4.5, − 0.1) |
- Plus adjustment for PAPP-A (< LOD substituted, log-transformed) and PAPP-A2 | 394 | − 1.9 | (− 4.1, 0.3) |
- Plus adjustment for IGFBP-2 | 394 | − 3.0 | (− 5.2, − 0.8) |
- Plus adjustment for IGFBP-3 | 394 | − 1.4 | (− 3.4, 0.6) |
In participants with available IGFBP-1 | 360 | − 2.1 | (− 4.4, 0.2) |
- Plus adjustment for IGFBP-1 (log-transformed) | 360 | − 0.9 | (− 3.1, 1.3) |
In participants with available IGFBP-5 | 125 | − 2.0 | (− 6.0, 2.2) |
- Plus adjustment for IGFBP-5 (log-transformed) | 125 | − 1.7 | (− 5.7, 2.3) |
In participants with available free IGF-1 | 339 | − 2.0 | (− 4.5, 0.5) |
- Plus adjustment for free IGF-1 (log-transformed) | 339 | − 2.3 | (− 4.8, 0.1) |
IGFBP-1, ng/mL‡║ | |||
As in Table 7 | 360 | 1.07 | (1.03, 1.11) |
- Plus adjustment for PAPP-A2 | 360 | 1.06 | (1.03, 1.11) |
- Plus adjustment for PAPP-A (< LOD substituted, log-transformed) | 360 | 1.07 | (1.03, 1.11) |
- Plus adjustment for PAPP-A (< LOD substituted, log-transformed) and PAPP-A2 | 360 | 1.07 | (1.03, 1.10) |
- Plus adjustment for IGF-1 | 360 | 1.06 | (1.02, 1.10) |
- Plus adjustment for IGFBP-2 | 360 | 1.09 | (1.05, 1.13) |
In participants with available IGFBP-5 | 116 | 1.09 | (1.02, 1.16) |
- Plus adjustment for IGFBP-5 (log-transformed) | 116 | 1.09 | (1.02, 1.16) |
In participants with available free IGF-1 | 309 | 1.04 | (1.00, 1.08) |
- Plus adjustment for free IGF-1 (log-transformed) | 309 | 1.04 | (1.00, 1.09) |
- Plus adjustment for free to total IGF-1 (%, log-transformed) | 309 | 1.04 | (1.00, 1.09) |
IGFBP-2, ng/ml | |||
As in Table 7 | 394 | − 8.9 | (− 14.5, − 3.3) |
- Plus adjustment for PAPP-A2 | 394 | − 10.2 | (− 15.7, − 4.6) |
- Plus adjustment for PAPP-A (< LOD substituted, log-transformed) | 394 | − 8.4 | (− 14.0, − 2.7) |
- Plus adjustment for PAPP-A (< LOD substituted, log-transformed) and PAPP-A2 | 394 | − 9.7 | (− 15.3, − 4.1) |
- Plus adjustment for IGF-1 | 394 | − 9.9 | (− 15.5, − 4.3) |
- Plus adjustment for IGFBP-3 | 394 | − 10.5 | (− 16.0, − 5.1) |
In participants with available free IGF-1 | 339 | − 13.9 | (− 19.9, − 8.0) |
- Plus adjustment for free IGF-1 (log-transformed) | 339 | − 13.5 | (− 19.5, − 7.6) |
- Plus adjustment for free to total IGF-1 (%, log-transformed) | 339 | − 13.6 | (− 19.5, − 7.6) |
In participants with available IGFBP-1 | 360 | − 9.6 | (− 15.4, − 3.7) |
- Plus adjustment for IGFBP-1 (log-transformed) | 360 | − 12.7 | (− 18.4, − 7.1) |
In participants with available IGFBP-5 | 125 | − 13.6 | (− 23.4, − 3.7) |
- Plus adjustment for IGFBP-5 (log-transformed) | 125 | − 13.3 | (− 23.1, − 3.4) |
IGFBP-3, ng/ml | |||
As in Table 7 | 394 | − 24.9 | (− 48.8, − 1.0) |
- Plus adjustment for PAPP-A2 | 394 | − 22.6 | (− 46.6, 1.4) |
- Plus adjustment for PAPP-A (< LOD substituted, log-transformed) | 394 | − 25.7 | (− 49.8, − 1.5) |
- Plus adjustment for PAPP-A (< LOD substituted, log-transformed) and PAPP-A2 | 394 | − 23.3 | (− 47.5, 1.0) |
- Plus adjustment for IGF-1 | 394 | − 12.8 | (− 34.1, 8.6) |
- Plus adjustment for IGFBP-2 | 394 | − 35.4 | (− 58.7, − 12.2) |
In participants with available free IGF-1 | 339 | − 5.5 | (− 31.2, 20.2) |
- Plus adjustment for free IGF-1 (log-transformed) | 339 | − 7.0 | (− 32.6, 18.6) |
- Plus adjustment for free to total IGF-1 (%, log-transformed) | 339 | − 5.6 | (− 31.4, 20.3) |
In participants with available IGFBP-1 | 360 | − 24.9 | (− 49.6, − 0.2) |
- Plus adjustment for IGFBP-1 (log-transformed) | 360 | − 15.8 | (− 40.3, 8.8) |
In participants with available IGFBP-5 | 125 | - 6.3 | (− 46.7, 34.1) |
- Plus adjustment for IGFBP-5 (log-transformed) | 125 | − 6.0 | (− 46.6, 34.7) |
